BIBLIOGRAPHY

1. Agrawal S. S., Talele G. S., Surana S J. Antioxidant Activity of Fractions from Tridax procumbens, Journal of Pharmacy Research, 2(1), 2009, 71-73.
2. Aspergillus Flavus And Aspergillus Niger, Asian Journal of Pharmaceutical and Clinical Research, 6(2), 2013, 123-125.
3. Austin LM, Ozawa M, Kikuchi T, Walters IB and Krueger JG, 1999. Invest. Dermatol., 113: 752-759.
4. Barker JN, 1991. The pathophysiology of psoriasis. Lancet, 338: 227-30.
5. Bhagwat D. A., Killedar S. G., Adnaik R. S. Anti-diabetic activity of leaf extract of Tridaxprocumbens, International Journal of Green Pharmacy, 2008, 126-128.
6. Boirivant M., Fuss I. J., Chu A., Strober W., Oxazolone colitis: a murine model of T helper cell type 2 colitis treatable with antibodies to interleukin 4. J. Exp. Med. 188 (1998) 1929–1939.
   bowel disease, J. Clin. Invest. 117 (2007) 514–521.
7. Cathrine L., Prabavathi N. Preliminary Phytochemical Analysis and Antibacterial Activity of leaf extracts of Vitex leucoxlon L. F. Int J Curr Pharm Res2011; l3: 71-73.
8. Christophers E, 2001. Psoriasis-epidemiology and clinical spectrum Clin Exp Dermatol, 26: 314-320
9. Coussens L. M., Werb Z. Inflammation and cancer. Nature 2002; 420: 860-867.
10. D'Arcy, P.F. (1991) Adverse reactions and interactions with herbal medicines. Part 1: adverse reactions. Adverse Drug Reactions and Toxicological Reviews 10: 4, 189-208.
11. D'Arcy, P.F. (1993) Adverse reactions and interactions with herbal medicines. Part 2: drug interactions. Adverse Drug Reactions and Toxicological Reviews 12: 3, 147-162.
12. Dasgupta A., Review of Abnormal Laboratory Test Results and Toxic Effects Due to Use of Herbal Medicines Am J Clin Pathol. 2003;120(1)
13. Dieleman L. A., Ridwan B. U., Tennyson G. S., Beagley K. W., Bucy R.P., Elson C. O., Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice, Gastroenterology 107 (1994) 1643–1652.

14. Dohi T., Fujihashi K., Kiyono H., Elson C. O., McGhee J. R., Mice deficient in TH1- and TH2-type cytokines develop distinct forms of hapten-induced colitis, Gastroenterology 119 (2000) 724–733.
15. Dohi T., Fujihashi K., Rennert P. D., Iwatani K, Kiyono K. H., McGhee J. R., Hapten- induced colitis is associated with colonic patch hypertrophy and T helper cell 2-type responses. J. Exp. Med. 189 (1999) 1169–1180.
16. Elson C. O., Cong Y., McCracken V.J., Dimmitt R. A., Lorenz R. G., Weaver C.T., Experimental models of inflammatory bowel disease reveal innate, adaptive, and regulatory mechanisms of host dialogue with the microbiota, Immunol. Rev. 206 (2005) 260–276.
17. Farnsworth, N. (1981) Foreword. In: Griggs, B. Green Pharmacy: A history of herbal medicine. London: Jill Norman and Hobhouse.
18. Ferrero-Miliani L., Nielsen O. H., Anderson P. S., Girardin S. E. Chronicinflammation: importance of NOD2 and NALP3 in interleukin- 1 beta generation. Clin. Exp. Immunol2007; 147 (2): 227-235.
19. Friedman ES, LaNatra N and Stiller MJ, 2002. NSAIDs in dermatologic therapy: review and preview. J Cutan Med Surg, 6: 449-459.
20. Fukata M., Michelsen K. S., Eri R, Thomas L. S., Hu B., Lukasek K, Nast C. C., Lechago J., Xu R., Naiki Y, Soliman, A., Arditi M., Abreu M. T., Tolllike receptor-4 is required for intestinal response to epithelial injury and limiting bacterial translocation in a murine model of acute colitis, Am. J. Physiol.: Gasterointest. Liver Physiol. 288 (2005) G1055–G1065.
21. Griffiths CE and Voorhees JJ, 1996. Psoriasis, T cells and autoimmunity. JR Soc Med*,* 89: 315-319.
22. Hernandez GL, Volpert OV, Iniguez MA, Lorenzo E, Martinez-Martinez S, Grau R, Fresno M and Redondo JM, 2001. Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporin A: roles of the nuclear factor of activatedT cells and cyclooxygenase 2. J Exp Med, 193: 607- 620.
23. Howes M. J. R., Houghton P. J. Plants used in Chinese and Indian traditional medicine for improvement of memory and cognitive function. Pharmacol Biochem Behav 2003; 75: 513-527.

24. Huerta C, Castellsague J., Varas-Lorenzo C., García Rodríguez L. A. Nonsteroidal Anti-Inflammatory Drugs and Risk of ARF in the General Population. Am J Kidney Dis. 2002; 45(3): 531-539.
25. Jess T., Loftus Jr E. V., Velayos F. S., Harmsen W. S., Zinsmeister A. R., Jindal A., Kumar P. In Vitro Antifungal Potential of Tridax Procumbens L. Against
26. Krueger G.G. and KP Callis, 2003. Development and use of alefacept to treat psoriasis. J. Am. Acad. Dermatol, 49: 87 - 97
27. Mahajan R., More D. Evaluation of Anticoagulant Activity Aqueous and Ethenolic Extracts and Their Isolated Phyto-chemicals of Some Medicinal Plants, International Journal of Pharmacy and Pharmaceutical Sciences, 4(4), 2012, 498- 500.
28. Mahesh B., Sathish S. Antimicrobial Activity of some important medicinal plant against plant and Human Pathogens. World J Agri Sci 2008; 4 (suppl): 839-843.
29. Mahler M., Bristol I. J., Leiter E. H., Workman A. E., Birkenmeier E. H., Elson C. O., Sundberg J P., Differential susceptibility of inbred mouse strains to dextran sulfate sodium-induced colitis, Am. J. Physiol. 274 (1998) G544–G551.
30. McGeer P. L., McGeer E. G. Local neuro inflammation and the progression of Alzheimer's disease. J Neurovirology 2002; 8(6): 529-538.
31. Mohd Saleh, Ahmad Kamal, Ahmad Rohi Ghazali , Noral Ashikin Yahya, Mohd Isa Wasiman & Zakiah Ismail 2012, 'Acute Toxicity Study of Standardized Mitragyna speciosa Korth Aqueous Extract in Sprague Dawley Rats', Journal of Plant Studies, vol. 1, no. 2, pp. 120-129
32. Morris G. P., Beck P. L., Herridge M. S., Depew W. T., Szewczuk M. R., Wallace J. L., Hapten-induced model of chronic inflammation and ulceration in the rat colon, Gastroenterology 96 (1989) 795–803.
33. Mueller M. M. Inflammation in epithelial skin tumours: Old stories and new ideas. EurJ Cancer 2006; 42(6): 735-744.
34. Murugensan D., Deviponnuswamy Renuka. Potential anti-inflammatory plant. A Int J Pharm Pharm Sci 2014; 6(4), 43-49

35. Nazeruddin G. M., Pingale S. S., Shaikh S. S., Pharmacological Review of Tridax Procumbens L, Pelagia Research Library, Der Pharmacia Sinica, 2(4), 2011, 172-175.
36. Neurath M. F., Fuss I., Kelsall B. L., Stuber E., Strober W., Antibodies to interleukin 12 abrogate established experimental colitis in mice, J. Exp. Med. 182 (1995) 1281–1290.
37. Neurath M.F., IL-23: a master regulator in Crohn disease, Nat. Med. 13 (2007) 26–28.
38. Nielsen O.H., Kirman I. , Rudiger N., Hendel J., Vainer B. , Upregulation Nieuwenhuis E. E., Neurath M. F., Corazza N., Iijima Trgovcich H. J., Wirtz S., Glickman J., Bailey D., Yoshida D. M, Galle P R.. Kronenberg R. M., Birkenbach M. M., Blumberg R. S., Disruption of T helper 2-immune responses in Epstein-Barr virus-induced gene 3-deficient mice, Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 16951–16956.
39. OECD 2001 Organization of Economic Cooperation and Development, Guidelines for Acute Oral Toxicity-425.
40. OECD 2008 Organization of Economic Cooperation and Development , Guidelines for Sub Acute Oral Toxicity-407.
41. Okayasu I., Hatakeyama S., Yamada M., Ohkusa T., Inagaki Y, Nakaya R., A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice, Gastroenterology 98 (1990) 694–702.
42. Oladunmoye M. K. Immunomodulatory Effects of Ethanolic Extract of Tridax procumbense on Swiss Albino Rats Orogastrically Dosed with Psudomonas aeruginosa (NCIB 950). Trends in Med Res 2006; 1:122 - 126.
43. Opong R. A., Nyarko A. K., Dodoo D., Gyang F. N., Koram K. A., Ayisi N. K. Antiplasmodial Activity of Extracts of Tridax Procumbens And Phyllanthus Amarus in In Vitro Plasmodium Falciparum Culture Systems, Ghana Medical Journal, 45(4), 2011, 143- 150.
44. Pai C., Kulkarni U., Borde M., Murali S., Mrudula P. and Yashwant Deshmukh. Antibacterial Activity of Tridax procumbens with Special Reference to Nosocomial Pathogens, British Journal of Pharmaceutical Research, 1(4), 2011, 164-173.

45. Palladino M. A., Bahjat F.R., Theodorakis E.A., Moldawer L. L. Anti-TNF- α therapies: the next generation. Nat Rev Drug Discovery 2003; 2: 736-746.
46. Panda S. K., Thatoi H.N., Dutta S. K. Antibacterial activity and phytochemical screening of leaf and bark extracts of Vitex negundo from Similipal biosphere reserve Orissa. J Med PlantRes 2009; 3(4):294-300.
47. Pilotto A., Sancarlo D., Addante F., Scarcelli C., Franceschi M. Nonsteroidal anti-inflammatory drug use in the elderly. Surgical Oncology 2010; 19: 167-172.
48. Podolsky D. K., Inflammatory bowel disease, N. Engl. J. Med. 347 (2002) 417–429.
49. Prabhu V. V., Nalini G., Chidambaranathan N., Kisan S. S. Evaluation of Anti-Inflammatory and Analgesic Activity of Tridax Procumbens Linn Against Formalin, Acetic Acid and CFA Induced Pain Models, International Journal of Pharmacy and Pharmaceutical Sciences, 3(2), 2011, 126- 130.
50. Ramaswamy Selvaratnam, Nettam Prathyusha, Ruthiramoorthi Saranya, Haridass Sumathy, Kutuva Tulasi Mohanavalli, Raju Jyothi Priya, et al. 2012, 'Acute toxicity and the 28-day repeated dose study of a Siddha medicine Nuna Kadugu in rats', Bio Med Central Complementary and Alternative Medicine, vol. 12, no. 190, pp. 1-13
51. Saikia B. Ethanomedical plants from Gohpur of Sonitpur district, Assam. Ind j Traditional knowledge 2006; 5(4): 529-530.
52. Sakuma S, Higashi Y, Sato N, Sasakawa T, Sengoku T, Ohkubo Y, Amaya T and Goto T, 2001. Tacrolimus suppressed the production of cytokines involved in atopic dermatitis by direct stimulation of human PBMC system. (Comparison with steroids). Inter Immunopharmacol, 1: 1219-26.
53. Sankaranarayanan S., Bama P., Sathyabama S., Bhuvaneswari N. Anticancer Compound Isolated From The Leaves of Tridax Procumbens Against Human Lung Cancer Cell A-549, Asian Journal of Pharmaceutical and Clinical Research, 6(2), 2013, 91-96.
54. Sartor R. B. Mechanisms of disease: pathogenesis of Crohn's disease and Shih S.C., Chang C. W. Nonsteroidal Anti-Inflammatory Drug- Related Gastrointestinal Bleeding in the Elderly. Int J Gerontology 2007;l (1): 40-45.

55. Schafer-Korting M, Schmid MH and Korting HC, 1996. Topical glucocorticoids with improved risk-benefit ratio. Rationale of a new concept. Drug Safety, 14:375-385.
56. Smyrk T. C., Schleck C. D., Tremaine W. J., Melton L. J., Munkholm P., Sandborn W. J., Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota, Gastroenterology 130 (2006) 1039–1046.
57. Tanaka T., Kohno H., Suzuki R., Yamada Y., Sugie S., Mori H., A novel inflammation-related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate, Cancer Sci. 94 (2003) 965–973.
58. Valsaraj R., Pushpangadan P., Smitt U. W., Adersen A., Nyman U. Antimicrobial screening of selected medicinal plants from India. J Ethnopharmacol 1997; 58: 75-83.
59. Wallace J. L. Pathogenesis of NSAID induced gastro-duodenal mucosal injury. Best Practice Res Clinical Gastroenterology 2001; 15: 691-703.
60. Williams K. L., Fuller C. R., Dieleman L. A., DaCosta C. M., Haldeman K. M., Sartor R. B., Lund P. K., Enhanced survival and mucosal repair after dextran sodium sulfate- induced colitis in transgenic mice that overexpress growth hormone, Gastroenterology 120 (2001) 925–937.
61. Wirtz S, Neurath F. M. Advanced Drug Delivery Reviews 59 (2007) 1073–1083
62. Wirtz S, Neurath M. F., Animal models of intestinal inflammation: new insights into the molecular pathogenesis and immunotherapy of inflammatory bowel disease, Int. J. Colorectal Dis. 15 (2000) 144–160.
63. Wirtz S., Neufert C., Weigmann B., Neurath M.F., Chemically induced mouse models of intestinal inflammation, Nat. Protoc. 2 (2007) 541–546.

Woodward M., Lowe G.D.O., Campbell D.J., Colman S., Rumley A., Chalmers J et al. Associations of inflammatory and hemostatic variables with the risk of recurrent stroke. Stroke 2005; 36(10): 21